Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia reported Q3 2026 total revenue of $83.7 million, up 14% year-over-year, with LUPKYNIS net product sales of $79.4 million, up 12%, and diluted EPS of $0.23, flat versus a year ago. The company raised its 2026 total revenue guidance to $325-$330 million from $315-$325 million and narrowed net product sales guidance to $310-$315 million. Nine-month net income rose 35% to $103.5 million on revenue growth of 19%.
Key figures
- Eps
- 0.23
- Revenue
- 83699000
- Guidance
- 2026 total revenue guidance raised from $315M-$325M to $325M-$330M; net product sales guidance narrowed from $305M-$315M to $310M-$315M
- Revenue Yoy
- 14%
- Q3 net income
- 31703000
- Nine month revenue
- 244624000
- Shares repurchased
- 5000000
- Operating income q3
- 35363000
- Cash and investments
- 486900000
- Q3 net product sales
- 79418000
- Net product sales yoy
- 12%
- Nine month net income
- 103472000
- Nine month eps diluted
- 0.76
- Nine month revenue yoy
- 19%
- Share repurchase spend
- 74880000
- Phase4 enrollment planned
- 150
- Operating cash flow nine months
- 131493000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.